Pharma BD Deal Intelligence
BioNTech's ~$250M tuck-in for Kite's neoantigen TCR platform and Gaithersburg manufacturing gave it a U.S. cell-therapy foothold, but by 2025 BioNTech was shuttering that same site and cutting 63 staff after its lead CLDN6 CAR-T candidate BNT211 stumbled in testicular tumors.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →BioNTech is broadening its cancer immunotherapy strategy with a deal to acquire Kite Pharma's solid tumor neoantigen T-cell receptor R&D platform and a…
Gilead Sciences said its Kite cell therapy unit will divest its solid tumor T-cell receptor research and development platform along with a manufacturing…
BioNTech said it will stop manufacturing cell therapies at its Gaithersburg, Maryland site -- acquired from Gilead's Kite Pharma in 2021 -- by the end of…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
BioNTech acquired Kite's individualized solid-tumor neoantigen TCR discovery platform and clinical manufacturing facility in Gaithersburg, MD, from Gilead. Announced July 19, 2021 and closed August 4, 2021; financial terms were not disclosed, with BioNTech later citing ~$250M in associated transaction costs (Q3 2021). The deal gave BioNTech a TCR-based cell-therapy capability and its first U.S. manufacturing footprint to pair with its mRNA cancer-vaccine platforms, while letting Gilead's Kite refocus on hematologic CAR-T (Yescarta, Tecartus). Post-close outcome: in June 2025 BioNTech announced it would cease cell-therapy manufacturing at the Gaithersburg site by end of 2025 and lay off 63 technical-operations staff, after dropping its lead CLDN6 CAR-T candidate BNT211 in germ-cell/testicular tumors following a Phase 1 signal-seeking readout. BNT211 development continues in other CLDN6-positive solid tumors, and the site is being realigned to other portfolio priorities (including ADCs such as BNT323), reflecting BioNTech's strategic pivot away from cell therapy toward mRNA and antibody-drug-conjugate modalities.
100K US cases/yr · $7.5B Global cell therapy market 2021 · ~$250M Estimated transaction value (terms not disclosed)
The BioNTech-Kite asset purchase targets solid tumors via individualized neoantigen T-cell receptor (TCR) cell therapy. The U.S. solid tumor population spans approximately 1.6 million new cancer cases per year (excluding hematologic malignancies), with the high-tumor-mutational-burden (TMB-high) subset representing the most tractable neoantigen-rich population — roughly 100,000-200,000 patients per year across NSCLC, MSI-H colorectal, melanoma, urothelial, and other tumors. TCR cell therapy is differentiated from CAR-T by targeting intracellular HLA-presented antigens (vs. surface antigens), enabling solid tumor reach beyond the CD19/BCMA-restricted heme malignancy paradigm dominated by Yescarta, Kymriah, Breyanzi, Tecartus, Carvykti, and Abecma. Individualized neoantigen approaches require patient tumor sequencing, in silico TCR matching or de novo design, autologous T-cell engineering, manufacturing, and infusion — a complex high-cost individualized therapy paradigm. The 2021 acquisition transferred Kite's Gaithersburg, MD clinical manufacturing facility (a major piece of cell therapy infrastructure) plus the platform IP to BioNTech for ~$250M, complementing BioNTech's existing FixVac fixed-shared-neoantigen mRNA cancer vaccine portfolio (BNT111, BNT112, BNT113, BNT114, BNT115, BNT116) and CAR-T programs (BNT211 in solid tumors). WAC pricing for autologous CAR-T therapies ranges $375K (Yescarta) to $475K+ (Carvykti); individualized neoantigen TCR therapies are anticipated to reach similar premium pricing.
The neoantigen-directed cancer immunotherapy landscape is one of the fastest-evolving spaces in oncology. Approved autologous cell therapies span CD19 CAR-Ts (axicabtagene ciloleucel/Yescarta, tisagenlecleucel/Kymriah, brexucabtagene autoleucel/Tecartus, lisocabtagene maraleucel/Breyanzi) and BCMA CAR-Ts (idecabtagene vicleucel/Abecma, ciltacabtagene autoleucel/Carvykti). Solid tumor TCR therapies competing in the neoantigen and shared antigen space include afami-cel (Tecelra, Adaptimmune, FDA approved 2024 for MAGE-A4 synovial sarcoma), lifileucel (Amtagvi, Iovance, FDA approved 2024 melanoma TIL), letetresgene autoleucel (NY-ESO-1, GSK, discontinued 2023), and TIL therapies from Achilles, Instil, Turnstone, and Neogene Therapeutics. Personalized neoantigen platforms include BioNTech's existing FixVac shared-neoantigen mRNA vaccines (BNT111 melanoma Phase 2), Moderna/Merck mRNA-4157 personalized cancer vaccine (KEYNOTE-942 melanoma Phase 2 positive 2023, Phase 3 ongoing), Gritstone Bio EDGE platform, Genocea Biosciences (defunct 2022), Achilles Therapeutics ATL001 (Phase 2 NSCLC/melanoma), and BioNTech's prior acquisition of Neon Therapeutics-style assets via internal pipeline. The Kite acquisition consolidates BioNTech as a vertically-integrated cancer immunotherapy company spanning shared and individualized neoantigen modalities plus CAR-T and TCR cell therapies.
Four years after acquiring Kite's neoantigen TCR platform and Gaithersburg, MD facility, BioNTech announced (June 2025) it will stop cell-therapy manufacturing at the site by year-end and lay off 63 staff, having dropped its lead CLDN6 CAR-T BNT211 in germ-cell/testicular tumors. The site is being realigned toward other priorities (ADCs); a strategic pivot away from cell therapy.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| BioNTech SE / Kite Pharma (Gilead Sciences) (this deal) | 2021 | $250M | — |
| BioNTech SE / Duality Biologics (Suzhou) Co. Ltd. | 2023 | $1.7B | — |
| BioNTech SE / Biotheus Inc. (Pumai Biotechnology) | 2024 | $950M | — |
| BioNTech SE / CureVac N.V. | 2025 | $1.2B | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
← Browse all deals · How we score deals
More: 2021 deals · BioNTech SE deals · Oncology deals